4 Jun 2023
Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma
Author: admintech | Filed under: Press ReleaseVorasidenib demonstrated an unprecedented improvement in progression free survival with a median of 27.7 months in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation; key secondary endpoint of time to next intervention significantly improved in the vorasidenib arm…